SCHOTT Pharma
Results of operations (in EUR m) | Q2 2026 | Q2 2025 | ∆ in % |
Revenue | 247.9 | 251.7 | -1.5% |
Share of High-value solutions (HVS) | 55% | 55% | - |
EBITDA | 64.6 | 71.8 | -10.1% |
EBITDA margin | 26.0% | 28.5% | - |
EBIT | 42.7 | 52.7 | -19.0% |
EBIT margin | 17.2% | 20.9% | - |
Financial result | -2.4 | -3.1 | -23.5% |
Income tax expenses | -9.2 | -11.3 | -18.8% |
Profit for the period | 31.1 | 38.3 | -18.7% |
Earnings per share (in EUR) | 0.21 | 0.25 | -16.0% |
Financial position (in EUR m) | Q2 2026 | Q2 2025 | |
Cash flows from operating activities | 91.7 | 47.5 | |
Cash flows from ongoing investing activities | -26.5 | -29.3 | |
Free cash flow | 65.2 | 18.2 | |
Net assets (in EUR m) | Mar. 31, 2026 | Sep. 30, 2025 | |
Working capital | 217.5 | 199.3 | |
Working capital in % of revenue | 21.9% | 20.2% | |
Equity ratio | 58.6% | 55.9% | |
Net debt | 110.0 | 122.2 | |
Employees | Mar. 31, 2026 | Sep. 30, 2025 | |
Revenue bridge
(in EUR m)
-0.0% -1.5% -1.5%
251.7
-0.1
247.9
-3.7
Q2 2025 Organic growth FX Q2 2026
Revenue by region
(in EUR m)
22.7
65.7
43.7
119.6
Q2
2025
22.0
49.1
37.3
139.5
Q2 2026
∆ in %
+16.6% -14.6% -25.3% -3.1%
EMEA APAC North America South AmericaHeadcount (as of the reporting date) 4,839 4,811
Drug Containment Solutions (DCS)
Results of operations (in EUR m) | Q2 2026 | Q2 2025 | ∆ in % |
Revenue | 149.2 | 142.8 | +4.5% |
EBITDA | 38.4 | 33.2 | +15.7% |
EBITDA margin | 25.7% | 23.2% | - |
EBIT | 28.2 | 23.8 | +18.5% |
EBIT margin | 18.9% | 16.7% | - |
Revenue bridge
(in EUR m)
+7.3% -2.8% +4.5%
149.2
142.8
+10.5
-4.1
Q2 2025 Organic growth FX Q2 2026
Drug Delivery Systems (DDS)
Results of operations (in EUR m) | Q2 2026 | Q2 2025 | ∆ in % |
Revenue | 98.8 | 109.1 | -9.5% |
EBITDA | 26.9 | 37.4 | -28.0% |
EBITDA margin | 27.2% | 34.2% | - |
EBIT | 15.4 | 27.9 | -44.7% |
EBIT margin | 15.6% | 25.5% | - |
Revenue bridge
(in EUR m)
-9.8% +0.3% -9.5%
109.1
+0.4
98.8
-10.7
1
Q2 2025 Organic growth FX Q2 2026
SCHOTT Pharma
Results of operations (in EUR m) | H1 2026 | H1 2025 | ∆ in % |
Revenue 488.1 | 483.1 | +1.0% | |
Share of High-value solutions (HVS) 56% | 55% | - | |
EBITDA 129.8 | 130.5 | -0.6% | |
EBITDA margin 26.6% | 27.0% | - | |
EBIT 86.5 | 92.9 | -6.9% | |
EBIT margin 17.7% | 19.2% | - | |
Financial result -4.1 | -6.5 | -36.1% | |
Income tax expenses -17.9 | -18.3 | -2.2% | |
Profit for the period 64.4 | 68.1 | -5.4% | |
Earnings per share (in EUR) 0.43 | 0.45 | -4.4% | |
Financial position (in EUR m) | H1 2026 | H1 2025 | |
Cash flows from operating activities | 95.1 | 72.6 | |
Cash flows from ongoing investing activities | -49.7 | -50.3 | |
Free cash flow | 45.4 | 22.3 | |
Net assets (in EUR m) | Mar. 31, 2026 | Sep. 30, 2025 | |
Working capital | 217.5 | 199.3 | |
Working capital in % of revenue | 21.9% | 20.2% | |
Equity ratio | 58.6% | 55.9% | |
Net debt | 110.0 | 122.2 | |
Employees | Mar. 31, 2026 | Sep. 30, 2025 | |
Revenue bridge
(in EUR m)
+2.3% -1.3% +1.0%
488.1
483.1
-6.1
+11.1
H1 2025 Organic growth FX H1 2026
Revenue by region
(in EUR m)
43.2
109.5
87.6
242.8
H1
2025
44.2
92.3
75.1
276.5
H1
2026
∆ in %
+13.9% -14.3% -15.8% +2.4%
EMEA APAC North America South AmericaHeadcount (as of the reporting date) 4,839 4,811
Drug Containment Solutions (DCS)
Results of operations (in EUR m) | H1 2026 | H1 2025 | ∆ in % |
Revenue | 286.4 | 271.1 | +5.7% |
EBITDA | 71.8 | 61.3 | +17.2% |
EBITDA margin | 25.1% | 22.6% | - |
EBIT | 52.3 | 42.9 | +22.1% |
EBIT margin | 18.3% | 15.8% | - |
Revenue bridge
(in EUR m)
+8.3% -2.7% +5.7%
-7.2
286.4
271.1
+22.6
H1 2025 Organic growth FX H1 2026
Drug Delivery Systems (DDS)
Results of operations (in EUR m) | H1 2026 | H1 2025 | ∆ in % |
Revenue | 201.8 | 212.2 | -4.9% |
EBITDA | 59.5 | 72.5 | -18.0% |
EBITDA margin | 29.5% | 34.2% | - |
EBIT | 36.1 | 53.7 | -32.9% |
EBIT margin | 17.9% | 25.3% | - |
Revenue bridge
(in EUR m)
-5.4% +0.5% -4.9%
212.2
+1.1
201.8
-11.5
H1 2025 Organic growth FX H1 2026
1
1